Ferric Carboxymaltose: Hypophosphataemia, Osteomalacia and Post-Marketing Risk

Ferric carboxymaltose (FCM) is an intravenous iron complex used when iron deficiency requires parenteral replacement. Its ability to deliver a substantial iron dose in one or two administrations can be clinically useful. The same treatment pattern, however, creates an opportunity for a product-associated disturbance of phosphate and bone-mineral metabolism that may be missed when follow-up focuses only on haemoglobin and iron indices.

The safety issue is not simply a low laboratory value. FCM can increase biologically active fibroblast growth factor 23 (FGF23), producing renal phosphate loss and changes in vitamin D and parathyroid hormone. Many biochemical episodes are transient, but some are severe or prolonged; sustained phosphate depletion can impair bone mineralisation and has been associated with hypophosphataemic osteomalacia and fractures. Fatigue, weakness and musculoskeletal pain may be attributed to the underlying iron deficiency, delaying recognition.

The regulatory history illustrates how pharmacovigilance can move from a recognised adverse reaction and risk-minimisation language to stronger controls when serious cases continue to emerge. In September 2026, the US Food and Drug Administration (FDA) required a boxed warning for Injectafer, the US reference product, after reviewing reports, literature and Sentinel data. In the European Union, the Pharmacovigilance Risk Assessment Committee (PRAC) began an Article 31 review of injectable iron medicines in September 2026; that review was still ongoing on 3 October 2026. These are distinct actions with different scope and legal effect.

Purpose and Scope

This article examines FCM-associated hypophosphataemia as a product-safety and pharmacovigilance problem. It explains the biological pathway, what comparative trials and post-marketing evidence can and cannot establish, how regulatory controls have evolved, and how a marketing authorisation holder (MAH) can evaluate reports and oversee risk-management activities.

The main focus is the FCM-related phosphate and bone signal. It is not a complete review of intravenous iron prescribing, iron-deficiency diagnosis, or all adverse reactions associated with parenteral iron. Other injectable iron products are discussed only where comparative evidence or the ongoing EU review makes the distinction relevant. Safety findings for one formulation should not automatically be attributed to every iron complex: formulation, dose, schedule, population and endpoint matter.

The article uses EU pharmacovigilance concepts while describing the US label change as a jurisdiction-specific action. Product information, approved indications, dosing and monitoring language can vary by product and jurisdiction. Clinical decisions remain with the treating healthcare professional and should be based on the current local product information and the patient's circumstances.

Therapeutic Context and the Safety Question

Intravenous iron is used when oral iron is not tolerated, has not produced an adequate response, cannot be used, or when iron repletion is needed within a clinical timeframe that oral treatment cannot meet. FCM is one of several iron-carbohydrate complexes. Its complex structure permits administration of comparatively large iron doses over a short course; iron is subsequently taken up and processed through normal iron-handling pathways.

The pharmacological benefit and the phosphate effect are related to the formulation but are not the same mechanism. The therapeutic objective is iron replacement. Hypophosphataemia is an off-target disturbance of mineral regulation associated with the FCM exposure. In a patient with iron-deficiency symptoms, a new episode of fatigue or muscle weakness can be difficult to interpret because the symptom may precede treatment, persist despite iron correction, or arise from a treatment-related phosphate disturbance.

The pharmacovigilance question is therefore longitudinal: did phosphate decline after exposure, how low did it become, how long did it persist, what symptoms or skeletal findings developed, what competing causes exist, and did the clinical course change after FCM was stopped or phosphate was corrected? A single post-infusion phosphate result can establish a laboratory event but cannot, by itself, explain its cause or determine whether bone injury has occurred.

Biological Mechanism

FGF23 and renal phosphate handling

FGF23 is a hormone produced predominantly by bone cells that helps regulate phosphate balance. It acts on the kidney to reduce tubular phosphate reabsorption and to suppress formation of active vitamin D, or 1,25-dihydroxyvitamin D (calcitriol). These effects ordinarily participate in maintaining mineral homeostasis.

The best-supported mechanism for FCM-associated hypophosphataemia is an increase in biologically active intact FGF23 after iron administration. The rise promotes urinary phosphate loss. Reduced calcitriol can decrease intestinal phosphate absorption and alter calcium balance; secondary changes in parathyroid hormone may then contribute to continued phosphate loss. This sequence is supported by prospective mechanistic studies measuring FGF23, phosphate, calcitriol and parathyroid hormone after FCM or comparator iron treatment.

The mechanism matters clinically because it explains why serum phosphate may continue to fall after the infusion rather than reaching its nadir immediately. It also explains why a patient can develop symptomatic hypophosphataemia despite normal renal function and normal phosphate before treatment. Reduced kidney function may modify phosphate handling and the observed biochemical risk, but chronic kidney disease should not be assumed to eliminate the possibility of clinically relevant hypophosphataemia.

From biochemical change to bone disease

Phosphate is required for skeletal mineralisation and multiple cellular functions. A short-lived, mild reduction in serum phosphate is not equivalent to osteomalacia. The concern increases when phosphate depletion is severe, persistent, recurrent, or accompanied by bone pain, proximal muscle weakness, raised alkaline phosphatase or fractures. If mineralisation remains impaired, osteoid is inadequately mineralised and bone becomes softer; this is the basis of osteomalacia.

Repeated courses can create cumulative clinical exposure even when each course is separated in time. The relevant history includes the number and timing of administrations, prior phosphate results, ongoing causes of phosphate depletion, and whether the patient received other medicines or had conditions that affect renal tubular function or mineral balance. A long interval between doses does not prove that phosphate fully recovered before the next course.

The risk pathway is probabilistic, not deterministic. Biochemical hypophosphataemia does not establish that osteomalacia is present, and FCM exposure alone does not establish skeletal injury. Conversely, the absence of an abnormal plain radiograph does not necessarily exclude early metabolic bone disease. Diagnosis requires clinical assessment and appropriate investigations rather than inference from the drug exposure alone.

Clinical Evidence and Phenotype

What comparative trials show

Randomised trials establish that biochemical hypophosphataemia occurs more often after FCM than after some alternative intravenous iron formulations in the studied populations. In the FIRM programme, a large randomised comparison of FCM with ferumoxytol found substantially more hypophosphataemia with FCM; a nested physiological study linked the phosphate effect to the FGF23 pathway. In two PHOSPHARE-IDA trials, hypophosphataemia through day 35 was reported in 75.0% and 73.7% of FCM-treated participants, compared with 7.9% and 8.1% of participants given iron isomaltoside 1000, now called ferric derisomaltose.

These trial proportions describe trial-defined biochemical outcomes in selected study populations, under specific dosing and measurement schedules. They are not estimates of the frequency of symptomatic hypophosphataemia, osteomalacia or fractures in routine practice. Definitions, follow-up duration, baseline characteristics, iron doses and testing intensity differ across studies. The comparative results also do not mean that alternative iron products are risk-free or interchangeable for an individual patient.

The clinical trials are valuable because scheduled sampling reveals the timing and duration of phosphate changes that routine care may not capture. Their limits are equally important: trials designed around laboratory outcomes are generally not sized or followed long enough to quantify uncommon, delayed skeletal outcomes. For those outcomes, case reports, spontaneous reports, regulatory review and longer-term observational evidence contribute different forms of evidence and uncertainty.

Time course and symptoms

A phosphate decline may develop over days to weeks after administration. In some patients it resolves without recognised symptoms; in others it persists or recurs, particularly when further iron courses are given before recovery or when additional risk factors remain. Patients may describe fatigue, weakness, myalgia, arthralgia, bone pain or reduced mobility. Severe depletion can have broader neuromuscular consequences, but attribution requires consideration of other causes and the measured phosphate level.

The clinical signal can be obscured by the indication for treatment. Persistent fatigue may be attributed to incompletely corrected anaemia; muscle and bone pain may be assigned to inflammatory disease, pregnancy, malignancy, immobility or another medicine. Osteomalacia can emerge gradually, and fracture or bone pain may prompt investigation only after repeated exposure. A useful safety history therefore covers symptoms that began or changed after treatment, not only the immediate infusion period.

A normal phosphate result obtained before infusion does not rule out a later decline. Likewise, a normal value at one follow-up point does not necessarily exclude an earlier transient episode. When a case concerns prolonged symptoms or suspected skeletal consequences, chronology and serial results are more informative than a single isolated laboratory value.

Risk factors and susceptibility

The current US Injectafer prescribing information identifies possible risk factors including gastrointestinal disorders associated with malabsorption of fat-soluble vitamins or phosphate, inflammatory bowel disease, medicines that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency, malnutrition and hereditary haemorrhagic telangiectasia. These factors can increase susceptibility or complicate recovery; they are not a diagnostic checklist and do not establish that an event is drug-induced.

Risk assessment should also take account of prior FCM exposure, repeat treatment, baseline phosphate, ongoing symptoms and other causes of phosphate loss. The FDA label specifically cautions that symptomatic hypophosphataemia has occurred in people with normal baseline phosphate and without apparent risk factors. Thus, risk-factor screening can identify patients needing closer attention, but a negative screen cannot be treated as assurance that no event will occur.

The distinction between susceptibility and causality is central to case evaluation. A patient may have several plausible contributors, such as malabsorption, vitamin D deficiency and FCM exposure. These do not necessarily compete as mutually exclusive explanations: FCM may precipitate or worsen phosphate depletion in a patient whose underlying condition reduces physiological reserve.

Clinical Detection and Risk Mitigation

Assessment before and after treatment

The 2026 US label instructs healthcare professionals to correct pre-existing hypophosphataemia before FCM administration and to check serum phosphate before a repeat course in patients at risk and in any patient receiving another course within three months. It also advises monitoring patients at risk for chronic low phosphate and treating hypophosphataemia as medically indicated. The label says to consider permanent discontinuation for severe symptomatic or persistent hypophosphataemia. These are current US label instructions for Injectafer; they should not be silently recast as identical legal requirements in every jurisdiction or for every intravenous iron product.

In EU practice, current product information for FCM already includes precautions relating to hypophosphataemia and hypophosphataemic osteomalacia, including monitoring language for high-dose or long-term treatment and people with known risk factors. The precise local wording should be checked in the applicable Summary of Product Characteristics. The September 2026 PRAC review is assessing both the risk and whether existing risk-minimisation measures are effective; its eventual recommendations were not yet available at the time of writing.

A proportionate operational approach is to link testing and follow-up to product information, exposure pattern, individual susceptibility and symptoms. The article does not establish a universal testing schedule after every infusion. A healthcare professional may consider phosphate measurement when symptoms are new or persistent, when there is a repeat course, when risk factors are present, or when ongoing treatment could prolong exposure. The decision and rationale should be clinically documented. A routine iron-response assessment alone will not detect an unmeasured phosphate abnormality.

Interpreting a suspected case

When hypophosphataemia is identified, the clinical evaluation should establish the result, units, laboratory reference range, date relative to each infusion and any repeat measurement. Relevant context may include iron studies, renal function, calcium, alkaline phosphatase, vitamin D metabolites, parathyroid hormone, urinary phosphate handling, symptoms, imaging and specialist assessment. Which tests are appropriate is a clinical decision; a pharmacovigilance case should not imply that every investigation is obligatory.

For suspected osteomalacia, the case should distinguish a confirmed diagnosis from symptoms or a raised biomarker that prompted assessment. Capture the diagnostic basis, bone imaging or other investigations where available, fracture details, treatment, outcome and the clinician's attribution. If the reporter supplies only “bone pain after iron,” the report should retain that description without upgrading it to osteomalacia.

Treatment of the phosphate disturbance, withholding or changing iron therapy, and any subsequent recovery are clinically relevant follow-up. A dechallenge may support temporal assessment, but phosphate may recover over time for several reasons; it is not conclusive on its own. Rechallenge solely to test causality would be inappropriate. If a subsequent FCM course occurs for clinical reasons, the exposure and outcome are important follow-up information.

Follow-up and information quality

A focused follow-up request can clarify the case without burdening the reporter with irrelevant questions. High-value information includes the exact iron product and formulation, dose and dates; prior or planned courses; baseline and serial phosphate results; onset and course of symptoms; evidence supporting osteomalacia or fracture; relevant comorbidities and concomitant medicines; management; outcome; and the reporter's assessment. The request should be proportionate to the seriousness and the data that could change medical or regulatory interpretation.

The absence of laboratory data does not invalidate an otherwise valid adverse-event report. It does limit clinical characterisation. If a reporter cannot provide a result, the case record should distinguish “not measured,” “unknown” and “measured but unavailable” rather than treating them as equivalent. A request for information should not delay required submission of a valid, reportable case.

Pharmacovigilance Evidence and Regulatory Evolution

From known risk to strengthened controls

The risk was not first recognised in 2026. European product information for FCM had previously been updated to address hypophosphataemia and hypophosphataemic osteomalacia, with advice relating to monitoring in patients receiving repeated or long-term treatment and those with risk factors. A 2020 EU periodic safety update single assessment (PSUSA) review considered literature and post-marketing data and recommended product-information changes, including warnings and instructions to re-evaluate FCM treatment when hypophosphataemia persists. In the United States, FDA labelling was strengthened before 2026, including phosphate-monitoring recommendations and mention of osteomalacia and fractures.

The September 2026 FDA action followed evidence that clinically significant cases continued to be reported despite earlier label changes. FDA reviewed multiple sources, including the adverse-event reporting system, literature and Sentinel data. The resulting US boxed warning states that FCM can cause severe, prolonged hypophosphataemia associated with serious outcomes, including hospitalisation, osteomalacia and fractures requiring clinical intervention. It also notes that cases occurred with normal baseline phosphate and without apparent risk factors.

FDA reported that its Sentinel analysis found serum phosphate testing in fewer than 20% of FCM administration episodes. This is a healthcare-utilisation observation about testing, not a measure of the incidence of hypophosphataemia or proof that a particular untested patient was harmed. Spontaneous reports are also subject to under-reporting, incomplete data, stimulated reporting and uncertain denominators. Together, these sources can identify a persistent safety-management problem, but their limitations must remain visible in any quantitative or causal interpretation.

The ongoing European Union review

At the time of writing, the PRAC had initiated an Article 31 referral concerning injectable iron-containing medicines. The procedure began on 3 September 2026 at the request of Austria’s medicines agency. The review covers nationally authorised products containing ferric carboxymaltose, ferric derisomaltose, ferric gluconate, ferric hydroxide polymaltose complex, iron dextran and iron sucrose. Oral iron products are outside the procedure.

EMA described serious reports of hypophosphataemia, including osteomalacia, after one or two FCM doses and in people without recognised risk factors. It also noted that symptoms can overlap with iron deficiency and that bone changes may not always be visible on X-rays. The PRAC is evaluating both the safety risk and the effectiveness of existing risk-minimisation measures. As the referral remained open on 3 October 2026, no final PRAC recommendation, CMDh position or European Commission decision should be implied.

The review's broader scope should not be read as a finding that all included formulations have the same risk magnitude or mechanism. It reflects the regulator's decision to assess similar reported cases across the class. Product-specific comparative trials can inform relative biochemical risk, while each product's own clinical evidence, spontaneous reports, exposure patterns and product information remain relevant.

What regulatory actions mean for pharmacovigilance

A US boxed warning is a prominent US prescribing-information control. It does not automatically amend European product information or establish a new EU legal requirement. Conversely, an ongoing Article 31 referral is a procedure for regulatory assessment, not a completed class-wide safety decision. MAHs should monitor the procedure and apply current local requirements while avoiding premature communication that presents a proposal or review as a final outcome.

The sequence also illustrates that a risk can be known yet incompletely controlled. Early warnings may identify a biochemical event and recommend monitoring. Later evidence can reveal that the event is severe or prolonged in some cases, that serious outcomes occur after limited exposure, or that the advised controls are not consistently implemented. The new question is then not only “is the adverse reaction plausible?” but “are current measures sufficiently effective to prevent or detect clinically important harm?”

This distinction is useful in signal management. Signal validation establishes whether the information warrants further assessment; evaluation integrates spontaneous reports, clinical studies, literature, exposure data, biological plausibility and alternative explanations. Risk-minimisation effectiveness is a separate question: it asks whether the intended control reaches the relevant population and changes practice or outcomes. A label update cannot be assumed effective merely because the text was approved and distributed.

Individual Case Processing and Signal Management

Case identification and coding

Cases may arrive through spontaneous reports, literature, patient-support or other organised data-collection systems, medical information, clinical programmes, or healthcare professionals. Intake controls should permit recognition of phosphate-related terms, including hypophosphataemia, blood phosphorus decreased, osteomalacia, bone pain, muscle weakness and fracture. Term selection should reflect the reporter's information and current MedDRA conventions; a symptom should not be coded as a confirmed diagnosis without support.

Identify the exact product where possible. The report should distinguish FCM from other injectable iron formulations, record brand and manufacturer when available, and capture administration dates, dose, route and course number. This matters because the signal is formulation-specific in much of the evidence, and the EU procedure includes products beyond FCM. A case initially received as “iron infusion” may require follow-up to identify the active substance.

Seriousness and expectedness must be assessed using applicable regional criteria and the relevant reference safety information (RSI) for the product, jurisdiction and time of the case. A medically important event may be serious even without hospitalisation if it meets the applicable seriousness criterion. The presence of hypophosphataemia in product information does not automatically determine the expectedness of a specific manifestation such as osteomalacia or fracture; the precise RSI wording and event description must be checked.

Signal evaluation

At aggregate level, analysis should separate laboratory hypophosphataemia from symptomatic cases and from established skeletal outcomes. Relevant dimensions include severity, persistence, time to onset, repeat exposure, dose and course pattern, baseline phosphate, comorbidities, concomitant medicines, clinical work-up and outcome. Cases with normal baseline results or no recognised susceptibility factors are especially informative for testing whether current screening assumptions are too narrow, but they still require verification and assessment of alternative causes.

Denominators and ascertainment should be described. Rates from scheduled clinical-trial testing cannot be compared directly with spontaneous-report counts. A reporting increase after label changes or public attention may reflect stimulated reporting as well as a change in underlying occurrence. Sentinel or claims data may improve population-level assessment, but exposure definitions, laboratory capture and confounding must be evaluated. Disproportionality can support prioritisation but is not a causal estimate.

The benefit-risk assessment should also retain the therapeutic context. Intravenous iron can address clinically significant iron deficiency when oral therapy is unsuitable or ineffective. The relevant decision is not whether phosphate risk exists in isolation, but how its frequency, severity, preventability and affected populations compare with the benefits and alternatives in the authorised setting. Avoid broad claims of superiority or equivalence unless the data support the exact comparison.

Product and system interfaces

Safety information may have implications for the product label, risk-management plan, educational materials or other risk-minimisation activities, but a change to each is not automatic. The MAH should evaluate whether the evidence meets the relevant regulatory threshold, whether existing measures are adequate, and what action is required by the competent authority or applicable procedure. Recommendations and local practice improvements should be identified as such unless they are mandated by the label or a regulatory decision.

The MAH's case-processing, signal-management, medical-information, quality and regulatory-affairs processes should connect. For example, medical information may receive reports of fatigue or bone pain that are not initially recognised as possible phosphate-related events; a product complaint may contain a safety report; and a repeat-course request may reveal a prior unexplained phosphate result. Reconciliation and escalation controls should allow these records to be connected without assuming that every query is an adverse event.

Cross-functional decisions should be traceable: the evidence reviewed, uncertainties, affected products and regions, decision rationale, actions, owners and effectiveness measures. If a decision is made not to change a control, the rationale should address why existing measures remain adequate in light of the new evidence.

Practical Implementation and Oversight

An illustrative case

The following scenario is hypothetical and demonstrates how a safety professional might structure evaluation; it is not a reported case. An adult receives an FCM course for iron-deficiency anaemia. Several weeks later the patient reports persistent weakness and diffuse bone pain. The initial contact describes the symptoms as continued anaemia. A subsequent laboratory result shows low serum phosphate, and a later assessment documents prolonged phosphate depletion and suspected osteomalacia.

The case processor should preserve the source chronology rather than compressing the account into “osteomalacia due to FCM.” The record should establish when each infusion occurred; whether a phosphate value was measured before treatment; when symptoms began; when the low result was obtained; how it changed on follow-up; what diagnostic evidence supports osteomalacia; and what treatment and outcome followed. It should capture relevant risk factors and competing explanations without allowing them to erase the temporal association.

If the clinician considers FCM causal, that assessment should be recorded as the reporter's view. The MAH's medical assessment should be separately documented and should explain what is known, what remains uncertain and what evidence would change the evaluation. If there is no confirmed osteomalacia, the report should retain the documented symptoms and laboratory event without upgrading the diagnosis.

At aggregate level, a case with limited exposure and no known risk factors may be important even if it does not establish a new causal mechanism. Repeated cases with similar time courses, persistent laboratory findings, and objective skeletal outcomes could affect signal prioritisation and the assessment of existing monitoring measures. The individual case and the aggregate signal answer different questions and should not be conflated.

Potential failure modes and controls

These examples are potential failure modes, not claims about actual inspection findings. Their relevance depends on the MAH's products, markets and safety system.

Inspection considerations

An inspector may examine whether the MAH's system can identify and evaluate this risk using the evidence available to it. Relevant evidence may include case-processing instructions, MedDRA search strategies, medical-information reconciliation, signal-detection outputs, periodic safety evaluation, regulatory-intelligence records, product-information versions, training, and documented oversight of risk-minimisation activities.

The important question is whether the records form a traceable chain. Can the organisation show that a case with low phosphate and bone pain was not lost because the terms entered through separate channels? Can it demonstrate that a signal evaluation considered trial and post-marketing evidence, formulation differences, exposure and uncertainty? If risk measures were retained or changed, is the decision rationale documented and linked to the current regulatory status in each jurisdiction?

Where a monitoring recommendation exists, evidence should show how the organisation assesses whether the measure is understood and operationally feasible. If effectiveness is evaluated, the chosen indicators should measure the intended behaviour or clinical result rather than only completion of communication tasks. An inspection question about monitoring does not itself create a universal requirement to test every patient after every infusion; the applicable label, regulatory decision and system-specific controls remain the reference points.

Governance and proportionate risk management

The MAH should maintain a current view of product-specific labels and open regulatory procedures. During the EU referral, regulatory affairs should track the PRAC and CMDh process, while pharmacovigilance continues routine case collection, evaluation and reporting under applicable requirements. Safety communications should distinguish established product information from a regulator's ongoing assessment.

For individual products, governance should link signal conclusions to concrete actions: whether to update product information, revise a risk-management activity, improve case capture, inform healthcare professionals through an appropriate channel, or continue monitoring. Each action needs an owner, due date and evidence of completion; effectiveness review should ask whether the intended risk-control outcome occurred. Where no additional action is selected, the documented rationale should address the evidence and uncertainty.

The operational balance is to avoid both under-recognition and overstatement. Under-recognition can occur when symptoms are attributed to iron deficiency or when repeat courses are evaluated without prior phosphate history. Overstatement can occur when a low laboratory value is treated as proof of skeletal injury, when all intravenous iron products are assumed to have identical risk, or when a pending EU review is reported as a final decision. Consistent terminology and jurisdiction-aware review help keep case handling medically useful and regulatorily accurate.

Practical Checklist

• Identify the exact iron formulation, brand, dose, route, administration dates and number of courses.
• Record baseline and post-treatment phosphate results with dates, units and reference ranges, if available.
• Establish symptom onset, evolution, investigations, management and outcome.
• Distinguish hypophosphataemia, symptoms, suspected osteomalacia and confirmed skeletal diagnosis.
• Capture prior FCM exposure, repeat courses, relevant conditions and medicines that may affect phosphate balance.
• Assess seriousness and expectedness against the applicable regional criteria and current product-specific RSI.
• Seek focused follow-up without delaying required reporting.
• Review cases across spontaneous, organised, medical-information and other relevant sources.
• Evaluate trial, literature, spontaneous-report and utilisation evidence according to their different limitations.
• Track US and EU regulatory actions separately; do not treat the open EU Article 31 review as a final decision.
• Document signal conclusions, risk-control decisions, owners and effectiveness evidence.

Key Takeaways

FCM-associated hypophosphataemia is a mechanistically supported and clinically relevant safety risk. FGF23-mediated renal phosphate loss explains the delayed biochemical course and provides biological plausibility for persistent depletion and skeletal consequences in some patients.

Comparative trials demonstrate higher rates of biochemical hypophosphataemia with FCM than with certain comparator formulations in the studied settings. Those trial rates are not estimates of symptomatic harm or osteomalacia incidence. Post-marketing reports can identify serious outcomes and weaknesses in detection but do not provide reliable incidence without suitable denominators.

The FDA added a boxed warning to US Injectafer labelling in 2026. The EU PRAC began a broader Article 31 review of injectable iron-containing medicines in September 2026; its outcome remained pending on 3 October 2026. A professional assessment must preserve these jurisdictional and procedural distinctions.

For pharmacovigilance practice, useful evaluation depends on exact product identification, exposure chronology, phosphate results, symptom evolution, clinical confirmation, competing causes, and follow-up. Risk controls should be tied to current local product information and evaluated for whether they work in practice.

References

1. US Food and Drug Administration. FDA Adds Boxed Warning to Labeling for Ferric Carboxymaltose Injection (Injectafer) to Describe Risk of Low Phosphate Levels. Drug Safety Communication, 1 September 2026. FDA communication.
2. US Food and Drug Administration. Injectafer (ferric carboxymaltose) Prescribing Information, revised August 2026. FDA-approved label PDF.
3. European Medicines Agency. Parenteral iron-containing medicinal products: Article 31 referral. Procedure initiated 3 September 2026; current status and documents. EMA referral page.
4. European Medicines Agency. PRAC starts review of injectable iron-containing medicines. Meeting highlights, 31 August–3 September 2026. EMA meeting highlights.
5. European Medicines Agency. Iron, parenteral preparations (except iron dextran): PSUSA scientific conclusions and grounds for variation, procedure PSUSA/00010236/202001. EU scientific conclusions and product-information changes.
6. Wolf M, et al. Randomized trial of intravenous iron-induced hypophosphatemia. Journal of Clinical Investigation. 2018;128(10):4231–4245. Full article.
7. Wolf M, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA. 2020;323(5):432–443. Full article.
8. Schaefer B, et al. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. Journal of Clinical Endocrinology & Metabolism. 2022;107(4):1009–1019. PubMed record.
9. Zoller H, et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023;72:644–653. PubMed record.
10. European Parliament and Council. Directive 2001/83/EC, Article 31, as amended. EUR-Lex consolidated text.

Regulatory Note

Regulatory status and product information are stated as of 3 October 2026. The FDA boxed warning described here applies to US Injectafer labelling and related generic labelling actions as specified by FDA. The EMA Article 31 review of parenteral iron-containing medicinal products had started but had not concluded by that date. Requirements and approved product information may differ by product and jurisdiction; readers should consult current local documents and subsequent regulatory decisions.